Camilla Bernardini Editor

# Duchenne Muscular Dystrophy

**Methods and Protocols** 



## METHODS IN MOLECULAR BIOLOGY

Series Editor
John M. Walker
School of Life and Medical Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK


For further volumes: http://www.springer.com/series/7651

# Duchenne Muscular Dystrophy Methods and Protocols

Edited by

### Camilla Bernardini

Istituto di Anatomia Umana e Biologia Cellulare Università Cattolica del Sacro Cuore Roma, Italy



Editor Camilla Bernardini Istituto di Anatomia Umana e Biologia Cellulare Università Cattolica del Sacro Cuore Roma, Italy

ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-7373-6 ISBN 978-1-4939-7374-3 (eBook) DOI 10.1007/978-1-4939-7374-3

Library of Congress Control Number: 2017955003

### © Springer Science+Business Media LLC 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Humana Press imprint is published by Springer Nature The registered company is Springer Science+Business Media LLC The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

### **Contents**

	acetributors	v xi
Par	T I REVIEWS AND OVERVIEW CHAPTERS	
1	An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy	3
2	Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy	19
Par	T II SKELETAL AND CARDIAC MUSCLE IN DMD	
3	Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies	31
	Sophie I. Mavrogeni, George Markousis-Mavrogenis, Antigoni Papavasiliou, George Papadopoulos, and Genovefa Kolovou	
4	Characterization of the Inflammatory Response in Dystrophic Muscle Using Flow Cytometry	43
5	Imaging Analysis of the Neuromuscular Junction in Dystrophic Muscle  Stephen J.P. Pratt, Shama R. Iyer, Sameer B. Shah, and Richard M. Lovering	57
Par	T III OMICS APPROACHES	
6	System Biology Approach: Gene Network Analysis for Muscular Dystrophy Federica Censi, Giovanni Calcagnini, Eugenio Mattei, and Alessandro Giuliani	75
7	Proteomic Profiling of the Dystrophin-Deficient Brain	91
8	Probing the Pathogenesis of Duchenne Muscular Dystrophy Using Mouse Models	107
	Alexander Morrison-Nozik and Saptarsi M. Haldar	107
Par	T IV EXON SKIPPING AND ANTISENSE OLIGONUCLEOTIDES (ASOs)	
9	Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy Shouta Miyatake, Yoshitaka Mizobe, Hotake Takizawa, Yuko Hara, Toshifumi Yokota, Shin'ichi Takeda, and Yoshitsugu Aoki	123

10	Designing Effective Antisense Oligonucleotides for Exon Skipping  Takenori Shimo, Rika Maruyama, and Toshifumi Yokota	143
11	Identification of Splicing Factors Involved in DMD Exon Skipping Events Using an In Vitro RNA Binding Assay  Julie Miro, Cyril F. Bourgeois, Mireille Claustres, Michel Koenig, and Sylvie Tuffery-Giraud	157
12	The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy	171
13	PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment  Yoichi Negishi, Yuko Ishii, Kei Nirasawa, Eri Sasaki, Yoko Endo-Takahashi, Ryo Suzuki, and Kazuo Maruyama	185
PAF	RT V BIOMARKERS AND DRUG DISCOVERY	
14	Proton Nuclear Magnetic Resonance ( <sup>1</sup> H NMR) Spectroscopy-Based Analysis of Lipid Components in Serum/Plasma of Patients with Duchenne Muscular Dystrophy (DMD)	195
15	Test of Antifibrotic Drugs in a Cellular Model of Fibrosis Based on Muscle-Derived Fibroblasts from Duchenne Muscular Dystrophy Patients Simona Zanotti and Marina Mora	205
16	Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy Wilson Savino, Fernanda Pinto-Mariz, and Vincent Mouly	219
PAF	RT VI LAST DISCOVERIES AND FUTURE PROSPECTIVES	
17	Advanced Methods to Study the Cross Talk Between Fibro-Adipogenic Progenitors and Muscle Stem Cells  Luca Tucciarone, Usue Etxaniz, Martina Sandoná, Silvia Consalvi, Pier Lorenzo Puri, and Valentina Saccone	231
18	AAV6 Vector Production and Purification for Muscle Gene Therapy	257
19	From gRNA Identification to the Restoration of Dystrophin Expression: A Dystrophin Gene Correction Strategy for Duchenne Muscular Dystrophy Mutations Using the CRISPR-Induced Deletion Method Benjamin Duchêne, Jean-Paul Iyombe-Engembe, Joël Rousseau, Jacques P. Tremblay, and Dominique L. Ouellet	267
Ind	ex	285